98%
921
2 minutes
20
A novel coronavirus discovered in late 2019 (COVID-19) quickly spread into a global epidemic and, thankfully, was brought under control by 2022. Because of the virus's unknown mutations and the vaccine's waning potency, forecasting is still essential for resurgence prevention and medical resource management. Computational efficiency and long-term accuracy are two bottlenecks for national-level forecasting. This study develops a novel multivariate time series forecasting model, the densely connected highly flexible dendritic neuron model (DFDNM) to predict daily and weekly positive COVID-19 cases. DFDNM's high flexibility mechanism improves its capacity to deal with nonlinear challenges. The dense introduction of shortcut connections alleviates the vanishing and exploding gradient problems, encourages feature reuse, and improves feature extraction. To deal with the rapidly growing parameters, an improved variation of the adaptive moment estimation (AdamW) algorithm is employed as the learning algorithm for the DFDNM because of its strong optimization ability. The experimental results and statistical analysis conducted across three Japanese prefectures confirm the efficacy and feasibility of the DFDNM while outperforming various state-of-the-art machine learning models. To the best of our knowledge, the proposed DFDNM is the first to restructure the dendritic neuron model's neural architecture, demonstrating promising use in multivariate time series prediction. Because of its optimal performance, the DFDNM may serve as an important reference for national and regional government decision-makers aiming to optimize pandemic prevention and medical resource management. We also verify that DFDMN is efficiently applicable not only to COVID-19 transmission prediction, but also to more general multivariate prediction tasks. It leads us to believe that it might be applied as a promising prediction model in other fields.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.neunet.2024.106527 | DOI Listing |
Diabetes Ther
September 2025
Eli Lilly and Company, Lilly Corporate Center, 893 Delaware Street, Indianapolis, IN, 46225, USA.
Introduction: This study examines the characteristics of adults with type 2 diabetes (T2D) who were not initially treated with an antihyperglycemic agent (AHA).
Methods: The analyses used Optum de-identified Market Clarity data from January 2013 through September 2023. The US study included nonpregnant adults with T2D who were continuously insured from 1 year prior through 5 years post diagnosis and did not fill a prescription for an AHA in the year after their initial T2D diagnosis.
Support Care Cancer
September 2025
Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan.
Purpose: To clarify the preferred timing and contents of early palliative care and preference for continued care delivery among patients with advanced cancer in Japan.
Methods: We conducted an Internet-based anonymous questionnaire survey on adult patients with advanced cancer. We assessed the patients' wishes for palliative care delivered by a team or at outpatient clinics while asymptomatic, as well as the preferred intervention timing and preference for continuing care lifelong.
World J Urol
September 2025
Department of Urology and Transplantation Surgery, Nantes University Hospital, Nantes, France.
Purpose: In 5-10% of cases, renal cancer extends into the venous system, particularly the inferior vena cava (IVC), which worsens prognosis. This study aims to assess morbidity, mortality, and oncological outcomes of patients treated surgically for renal cancer with IVC extension over a 30-year period, in two experienced centers.
Materials And Methods: This bicentric, retrospective study analyzed patients treated between 1988 and 2020 for renal cancer involving the IVC.
Rheumatol Int
September 2025
Division of Rheumatology and Immunology, Department of PMR, , Sakarya University School of Medicine, Sakarya, Turkey.
To identify clinical and demographic predictors associated with the timing of transition from psoriasis (PsO) to psoriatic arthritis (PsA), and to compare the characteristics of patients with concurrent PsO-PsA onset versus those with prolonged transition. A multi-center, observational study was conducted using data from the Turkish League Against Rheumatism (TLAR) network including PsA patients fulfilling CASPAR criteria. Patients were categorized into two groups: Group 1 (concurrent PsO and PsA onset within ± 1 year) and Group 2 (prolonged transition to PsA, > 1 year after PsO).
View Article and Find Full Text PDFJ Surg Oncol
September 2025
School of Medicine, Creighton University; Omaha, Nebraska, USA.
Introduction: Time to initiation of therapy in oncological care is an influential factor in disease progression and survival outcomes in many cancer types. We aim to identify factors associated with delayed time to treatment (TTT) in high-grade osteosarcoma and its relationship to disease-specific survival (DSS).
Methods: The SEER database was queried for biopsy-confirmed cases of high-grade osteosarcoma between 2000 and 2021 using ICD-O-3 histology codes 9180/3-9194/3 and primary site codes C40.